Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
- PMID: 20122289
- PMCID: PMC2874260
- DOI: 10.1186/alzrt24
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
Abstract
Evidence for the involvement of inflammatory processes in the pathogenesis of Alzheimer's disease (AD) has been documented for a long time. However, the inflammation hypothesis in relation to AD pathology has emerged relatively recently. Even in this hypothesis, the inflammatory reaction is still considered to be a downstream effect of the accumulated proteins (amyloid beta (Abeta) and tau). This review aims to highlight the importance of the immune processes involved in AD pathogenesis based on the outcomes of the two major inflammation-relevant treatment strategies against AD developed and tested to date in animal studies and human clinical trials - the use of anti-inflammatory drugs and immunisation against Abeta.
Similar articles
-
Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.Ann Integr Mol Med. 2020;2(1):90-114. doi: 10.33597/aimm.02-1007. Ann Integr Mol Med. 2020. PMID: 32617536 Free PMC article.
-
Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.Ann Integr Mol Med. 2019;1(1):61-74. Epub 2019 Nov 20. Ann Integr Mol Med. 2019. PMID: 31858090 Free PMC article.
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
The antimicrobial protection hypothesis of Alzheimer's disease.Alzheimers Dement. 2018 Dec;14(12):1602-1614. doi: 10.1016/j.jalz.2018.06.3040. Epub 2018 Oct 9. Alzheimers Dement. 2018. PMID: 30314800
-
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review.
Cited by
-
Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment.Aging Dis. 2015 Aug 1;6(4):282-99. doi: 10.14336/AD.2014.002. eCollection 2015 Aug. Aging Dis. 2015. PMID: 26236550 Free PMC article. Review.
-
Genome-wide methylomic regulation of multiscale gene networks in Alzheimer's disease.Alzheimers Dement. 2023 Aug;19(8):3472-3495. doi: 10.1002/alz.12969. Epub 2023 Feb 22. Alzheimers Dement. 2023. PMID: 36811307 Free PMC article.
-
Mild systemic oxidative stress in the subclinical stage of Alzheimer's disease.Oxid Med Cell Longev. 2013;2013:609019. doi: 10.1155/2013/609019. Epub 2013 Dec 18. Oxid Med Cell Longev. 2013. PMID: 24454987 Free PMC article.
-
Pinpointing key mechanisms in Alzheimer's disease development.Alzheimers Res Ther. 2010 Mar 31;2(2):4. doi: 10.1186/alzrt27. Alzheimers Res Ther. 2010. PMID: 20359316 Free PMC article.
-
Beneficial effect of antibodies against β- secretase cleavage site of APP on Alzheimer's-like pathology in triple-transgenic mice.PLoS One. 2012;7(10):e46650. doi: 10.1371/journal.pone.0046650. Epub 2012 Oct 10. PLoS One. 2012. PMID: 23071606 Free PMC article.
References
-
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I. et al.Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421. doi: 10.1016/S0197-4580(00)00124-X. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources